# KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy

Source: https://onco.cc/trials/nct05427383/  
OnCo record `nct05427383` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Docetaxel in gastric & gastro-oesophageal junction cancer, run by Shanghai JMT-Bio Inc., now recruiting.

## Summary

KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy is a phase 2/3 interventional study registered as NCT05427383 by Shanghai JMT-Bio Inc., with 286 participants planned, started 2022-04-07 and due to reach its primary completion in 2025-11. Interventions recorded: KN026/Placbo Injection, Paclitaxel Injection, Docetaxel Injection and Irinotecan Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05427383
- Phase: 2/3
- Setting: A Randomized, Multicenter, Phase Ⅱ/Ш Clinical Study to Evaluate the Efficacy of KN026 in Combination With Chemotherapy in Subjects With HER2 Positive Advanced Unresectable or Metastatic Gastric Cancer (Including Gastro-esophageal Junction Adenocarcinoma) Who Have Failed First-line Therapy.
- Sponsor: Shanghai JMT-Bio Inc.
- Enrolled: 286

## Sources

- ClinicalTrials.gov NCT05427383: https://clinicaltrials.gov/study/NCT05427383

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/)
- companies: [CSPC Pharmaceutical Group](https://onco.cc/companies/cspc/)

---
JSON: https://onco.cc/api/v1/entities/nct05427383.json